Theravax

Theravax is a biotechnology company focused on developing personalized whole-cell vaccines for the treatment of cancer, with a primary focus on pediatric brain tumors such as medulloblastoma. The company's proprietary platform involves harvesting a patient's tumor cells and engineering them to secrete potent immune-stimulating factors, thereby training the immune system to recognize and eliminate cancer cells. By leveraging the full spectrum of a patient's unique tumor antigens, Theravax aims to provide a more comprehensive and durable immune response compared to single-antigen vaccines. The company was founded based on research from Nationwide Children's Hospital and Case Western Reserve University.